Date Approved


Date Posted


Degree Type

Campus Only Thesis

Degree Name

Master of Science (MS)

Department or School


Committee Member

Cory Emal, PhD, Chair

Committee Member

Harriet Lindsay, PhD

Committee Member

Deborah Heyl-Clegg, PhD


Plasminogen activator inhibitor (PAI-1) is a member of the serine protease inhibitor (serpin) family of proteins, which inhibits certain serine proteases, such as tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), and thus is a primary regulator of fibrinolysis, the process that results in breakdown of blood clots. PAI-1 also exhibits effects on various human ailments including atherosclerosis, stroke and diabetes, with which high levels of PAI-1 have been associated. The goal of this research study is to design novel, potent, and specific small molecule inhibitors of PAI-1. The structural intricacy of the PAI-1 allows for multiple prospective binding sites. This research study explores the synthesis and screening of biological activity of various structural analogues of the lead molecule I-26, which was identified through high-throughput screening. It was hypothesized that the structural alterations of the lead molecule would affect the potency of PAI-1 inhibitor. The design rationale, synthesis and structure-activity relationships of novel small molecule inhibitors of PAI-1 are discussed.